Oslo, Norway, December 19, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that that its Chief
Executive Officer, Michael Engsig will present at the 42nd Annual J.P. Morgan
Healthcare Conference and is available for 1:1 investor meetings. 

Date:		Wednesday, January 10, 2024
Time:		3:45 pm PST
Webcast:	https://jpmorgan.metameetings.net/events/healthcare24/sessions/49580-ny
kode-therapeutics/webcast?gpu_only=true&kiosk=true

The presentation, as well as a live audio and archived webcast of the
presentation can be accessed in the Investors section of the Company's website:
https://nykode.com/investors/financial-reports-and-presentations/


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), which have been
shown to induce a broad, strong and long-lasting antigen specific immune
response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen
vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group. 

The Company's partnerships include Genentech within oncology and a multi-target
collaboration with Regeneron in oncology and infectious diseases.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA 
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway